The Carcinogenic Potency Project

p-Rosaniline.HCl (CAS 569-61-9)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
ezy liv ski sub thy ezy sub thy liv adr liv 39.4m 51.5m

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
(mg/kg/day)
Male Female
no positive no positive no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   adr = adrenal gland. ezy = ear/Zymbal’s gland. liv = liver. ski = skin. sub = subcutaneous tissue. thy = thyroid gland. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

p-Rosaniline.HCl: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



p-ROSANILINE.HCl  (p-magenta, C.I. basic red 9.HCl) 569-61-9
5538 H f syg gav 84w84 1151                          0    85.7mg                                            Green;zkko,95,51-55;1979
 liv tum e      no dre   P=1.       461.mg n.s.s.   0/40    0/40
 lun tum e      no dre   P=1.       461.mg n.s.s.   0/40    0/40
 tba mix e      no dre   P=1.    -  187.mg n.s.s.   5/40    4/40
5539 H m syg gav 84w84 1151                          0    85.7mg
 liv tum e      no dre   P=1.       461.mg n.s.s.   0/40    0/40
 lun tum e      no dre   P=1.       461.mg n.s.s.   0/40    0/40
 tba mix e      no dre   P=1.    -  331.mg n.s.s.   3/40    1/40
5540 M f b6c eat 24m24 TR285 :                       0    63.8mg  128.mg
 liv MXA        20.3mg * P<.0005    13.5mg 32.3mg   5/50   35/50   41/50                                              liv:hpa,hpc. S
 MXB MXB        28.8mg * P<.0005    18.9mg 46.5mg   4/50   25/50   37/50                                     adr:phe,phm; liv:hpc. C
 liv hpc        32.3mg * P<.0005 c  20.9mg 52.5mg   3/50   19/50   37/50
 liv hpa        35.9mg \ P<.0005    18.6mg 85.9mg   2/50   18/50   (4/50)                                                          S
 --- MXA        62.2mg * P<.0005 e  33.7mg 179.mg  17/50   24/50   25/50                                  ---:mlh,mlm,mlp,mlu,mno.
 adr MXA        90.6mg * P<.0005 c  45.0mg 245.mg   1/50    8/50    8/50                                              adr:phe,phm.
 --- mlp        151.mg \ P<.002  e  51.6mg 810.mg   0/50    5/50   (1/50)
 lun MXA        302.mg * P<.002     108.mg 1.35gm   0/50    2/50    5/50                                              lun:a/a,a/c. S
 hag MXA        316.mg / P<.002     106.mg 1.58gm   0/50    0/50    5/50                                              hag:adn,cyn. S
 lun a/a        326.mg * P<.003     111.mg 1.95gm   0/50    2/50    4/50                                                           S
 --- mlh        380.mg * P<.004  e  163.mg 2.64gm   1/50    3/50    8/50
 hag ade        548.mg * P<.01      147.mg 45.2gm   0/50    0/50    3/50                                                           S
 hag MXA        388.mg / P<.02      121.mg n.s.s.   1/50    0/50    5/50                                          hag:adn,can,cyn. S
 TBA MXB        23.4mg * P<.0005    14.7mg 44.0mg  31/50   50/50   49/50
 liv MXB        20.3mg * P<.0005    13.5mg 32.3mg   5/50   35/50   41/50                                          liv:hpa,hpc,nnd.
 lun MXB        302.mg * P<.002     108.mg 1.35gm   0/50    2/50    5/50                                              lun:a/a,a/c.
5541 M m b6c eat 24m24 TR285 :                       0    58.9mg  118.mg
 liv hpc        127.mg * P<.002  c  69.0mg 582.mg  10/50   20/50   27/50
 liv MXA        116.mg * P<.04      50.1mg n.s.s.  29/50   37/50   41/50                                              liv:hpa,hpc. S
 --- mlm        610.mg * P<.02      263.mg n.s.s.   0/50    3/50    4/50                                                           S
 TBA MXB        222.mg * P<.4       56.8mg n.s.s.  44/50   43/50   46/50
 liv MXB        116.mg * P<.04      50.1mg n.s.s.  29/50   37/50   41/50                                          liv:hpa,hpc,nnd.
 lun MXB        no dre   P=1.       284.mg n.s.s.  11/50    7/50    8/50                                              lun:a/a,a/c.
5542 R f f34 eat 24m24 TR285 :                       0    24.6mg  49.3mg
 mgl MXA        25.4mg * P<.0005 e  14.1mg 83.6mg  23/50   32/50   32/50                                          mgl:acn,adn,fba.
 mgl fba        27.9mg * P<.0005 e  15.0mg 108.mg  22/50   31/50   29/50
 MXB MXB        32.2mg * P<.0005    21.2mg 51.7mg   0/50   16/50   21/50                            sub:fib; thy:fca,fcc; zym:can. C
 sub MXA        40.9mg * P<.0005    25.1mg 82.0mg   1/50   17/50   12/50                                          sub:fbs,fib,srn. S
 sub MXA        42.8mg * P<.0005    26.5mg 76.6mg   0/50   16/50   10/50                                              sub:fbs,fib. S
 sub fib        44.5mg * P<.0005 c  27.2mg 80.7mg   0/50   15/50   10/50
 ute ess        133.mg * P<.006     60.0mg 1.50gm   1/50    5/50    6/50                                                           S
 thy MXA        154.mg * P<.0005 c  68.8mg 534.mg   0/50    2/50    6/50                                              thy:fca,fcc.
 zym can        190.mg * P<.002  c  86.5mg 651.mg   0/50    2/50    7/50
 thy fca        318.mg / P<.007     108.mg 5.07gm   0/50    0/50    4/50                                                           S
 mgl MXA        156.mg * P<.03   e  63.2mg n.s.s.   2/50    4/50    6/50                                              mgl:acn,adn.
 liv MXA        189.mg * P<.04      73.0mg n.s.s.   1/50    4/50    4/50                                              liv:hpc,nnd. S
 mgl acn        232.mg * P<.06   e  79.3mg n.s.s.   2/50    2/50    5/50
 TBA MXB        17.8mg * P<.0005    10.1mg 57.5mg  41/50   50/50   48/50
 liv MXB        189.mg * P<.04      73.0mg n.s.s.   1/50    4/50    4/50                                          liv:hpa,hpc,nnd.
5543 R m f34 eat 24m24 TR285 :                       0    39.2mg  79.2mg
 tes ict        15.6mg / P<.0005    9.57mg 33.0mg  43/50   46/50   37/50                                                           S
 MXB MXB        21.2mg / P<.0005    14.8mg 32.0mg   3/50   26/50   40/50  liv:hpc; ski:sea,sqc,tri; sub:fib; thy:fca,fcc; zym:can. C
 sub MXA        33.0mg / P<.0005    20.6mg 59.7mg   3/50   22/50   16/50                                              sub:fbs,fib. S
 sub MXA        33.4mg / P<.0005    20.8mg 62.6mg   6/50   24/50   19/50                                          sub:fbs,fib,srn. S
 sub fib        35.3mg / P<.0005 c  22.2mg 62.9mg   2/50   20/50   16/50
 liv MXA        41.5mg / P<.0005    24.0mg 89.4mg   5/50   15/50   14/50                                              liv:hpc,nnd. S
 thy MXA        57.0mg / P<.0005 c  34.9mg 97.5mg   0/50    5/50   25/50                                              thy:fca,fcc.
 liv nnd        62.2mg * P<.0005    31.0mg 246.mg   5/50   14/50    6/50                                                           S
 thy fcc        73.9mg / P<.0005 c  42.1mg 137.mg   0/50    5/50   18/50
 ski MXA        93.8mg / P<.0005    47.9mg 235.mg   2/50    2/50   14/50                                              ski:sqc,sqp. S
 zym can        124.mg / P<.0005 c  61.6mg 314.mg   1/50    1/50   13/50
 ski sqc        130.mg / P<.0005 c  61.7mg 317.mg   0/50    1/50   10/50
 liv hpc        140.mg / P<.0005 c  65.7mg 357.mg   0/50    2/50    8/50
 pni MXA        152.mg * P<.006     62.5mg 2.26gm   2/50    5/50    4/50                                              pni:isa,isc. S
 thy fca        176.mg / P<.0005 c  78.3mg 477.mg   0/50    0/50    9/50
 ski tri        221.mg / P<.0005 c  90.5mg 711.mg   0/50    0/50    7/50
 lun a/a        281.mg * P<.006     98.7mg 2.79gm   0/50    3/50    3/50                                                           S
 ski sea        424.mg / P<.003  c  157.mg 2.29gm   0/50    0/50    5/50
 MXA MXA        184.mg * P<.02      70.1mg 42.6gm   1/50    5/50    3/50                   bod:men; mls:men; mul:men; tnv:men,msm. S
 pni isc        252.mg * P<.02      85.2mg n.s.s.   0/50    3/50    1/50                                                           S
 lun MXA        254.mg * P<.02      90.9mg n.s.s.   1/50    3/50    4/50                                              lun:a/a,a/c. S
 ski bcc        385.mg / P<.03      116.mg n.s.s.   1/50    0/50    4/50                                                           S
 liv MXA        557.mg / P<.02      162.mg n.s.s.   0/50    0/50    3/50                                              liv:bda,bdc. S
 TBA MXB        15.7mg / P<.0005    9.99mg 29.7mg  41/50   47/50   45/50
 liv MXB        41.5mg / P<.0005    24.0mg 89.4mg   5/50   15/50   14/50                                          liv:hpa,hpc,nnd.
5544 R f sda gav 30m30 1524                          0    48.6mg                                         Ketkar;clet,16,203-206;1982
 liv tum ev     no dre   P=1.       597.mg n.s.s.   0/40    0/40
 tba mix ev     no dre   P=1.    -  244.mg n.s.s.  23/40   11/40
5545 R m sda gav 29m29 1524                          0    48.7mg
 liv tum ev     no dre   P=1.       571.mg n.s.s.   0/40    0/40
 tba mix ev     no dre   P=1.    -  201.mg n.s.s.  10/40    7/40
Mutagenicity in Salmonella: positive
SMILES Code for p-Rosaniline.HCl: C(C1=CC=C(C=C1)N)(C2=CC=C(C=C2)N)=C3C=CC(C=C3)=N.[HCl]
InChI Code for p-Rosaniline.HCl: InChI=1/C19H17N3.ClH/c20-16-7-1-13(2-8-16)19(14-3-9-17(21)10-4-14)15-5-11-18(22)12-6-15;/h1-12,20H,21-22H2;1H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for p-Rosaniline.HCl: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007